Nakagawa Kimie, Sasaki Yuko, Kato Shigeaki, Kubodera Noboru, Okano Toshio
Department of Hygienic Sciences, Kobe Pharmaceutical University, Japan.
Carcinogenesis. 2005 Jun;26(6):1044-54. doi: 10.1093/carcin/bgi049. Epub 2005 Feb 17.
1alpha,25-Dihydroxyvitamin D(3) (1alpha,25-D(3)) has potent antiproliferative and anti-invasive properties in vitro in cancer cells. However, its calcemic effect in vivo limits its therapeutic applications. Here, we report the efficacy of 22-oxa-1alpha,25-dihydroxyvitamin D(3) (22-oxa-1alpha,25-D(3)), a low calcemic analog of vitamin D, against the development of metastatic lung carcinoma after an intravenous injection of green fluorescent protein-transfected Lewis lung carcinoma (LLC-GFP) cells in C57BL/6 mice. The mice injected with tumor cells were implanted simultaneously with osmotic minipumps containing either 1alpha,25-D(3), 22-oxa-1alpha,25-D(3) or vehicle. The 1alpha,25-D(3) treatment group had been hypercalcemic, but the 22-oxa-1alpha,25-D(3) and vehicle treatment groups remained normocalcemic for the duration of the experiment. The total number of lung metastases, lung weight and the expression of GFP mRNA in the lung were markedly decreased in 1alpha,25-D(3) and 22-oxa-1alpha,25-D(3)-treated mice. In the in vitro experiment, 1alpha,25-D(3) and 22-oxa-1alpha,25-D(3) reduced the expression of matrix metalloproteinase (MMP)-2, MMP-9, vascular endothelial growth factor and parathyroid hormone-related protein in LLC-GFP cells. Furthermore, in the angiogenesis assay, the number of tumor cells or basic fibroblast growth factor-induced angiogenesis was reduced in 1alpha,25-D(3) and 22-oxa-1alpha,25-D(3)-treated mice. Moreover, using a new experimental model of vitamin D receptor (VDR) null mutant (VDR(-/-)) mice with corrected hypocalcemia and hypervitaminosis D, we examine the anti-cancer effect of 22-oxa-1alpha,25-D(3) without other functions induced by 22-oxa-1alpha,25-D(3) in the host. In the VDR(-/-) mice, 22-oxa-1alpha,25-D(3) directly inhibited the metastatic activity of LLC-GFP cells in a dose-dependent manner without exerting a direct influence on the calcemic activity or other actions regulated by 22-oxa-1alpha,25-D(3) in the host. These results indicate that the inhibition of metastasis and angiogenesis-inducing activity in cancer cells seemed to be a major mechanism responsible for the anti-cancer effects of 22-oxa-1alpha,25-D(3). Our findings show that 22-oxa-1alpha,25-D(3) is beneficial for the prevention of metastasis in lung carcinoma.
1α,25 - 二羟基维生素D(3)(1α,25 - D(3))在体外对癌细胞具有强大的抗增殖和抗侵袭特性。然而,其在体内的血钙升高作用限制了其治疗应用。在此,我们报告了维生素D的低血钙类似物22 - 氧杂 - 1α,25 - 二羟基维生素D(3)(22 - 氧杂 - 1α,25 - D(3))在将绿色荧光蛋白转染的Lewis肺癌(LLC - GFP)细胞静脉注射到C57BL / 6小鼠体内后,对转移性肺癌发展的疗效。注射肿瘤细胞的小鼠同时植入含有1α,25 - D(3)、22 - 氧杂 - 1α,25 - D(3)或赋形剂的渗透微型泵。1α,25 - D(3)治疗组出现高钙血症,但22 - 氧杂 - 1α,25 - D(3)和赋形剂治疗组在实验期间保持正常血钙水平。在1α,25 - D(3)和22 - 氧杂 - 1α,25 - D(3)治疗的小鼠中,肺转移灶总数、肺重量以及肺中GFP mRNA的表达均显著降低。在体外实验中,1α,25 - D(3)和22 - 氧杂 - 1α,25 - D(3)降低了LLC - GFP细胞中基质金属蛋白酶(MMP)-2、MMP - 9、血管内皮生长因子和甲状旁腺激素相关蛋白的表达。此外,在血管生成测定中,1α,25 - D(3)和22 - 氧杂 - 1α,25 - D(3)治疗的小鼠中肿瘤细胞数量或碱性成纤维细胞生长因子诱导的血管生成减少。此外,我们使用一种新的维生素D受体(VDR)基因敲除突变体(VDR(-/-))小鼠实验模型,该模型已纠正低钙血症和维生素D过多症,以研究22 - 氧杂 - 1α,25 - D(3)在宿主中不产生其他功能时的抗癌作用。在VDR(-/-)小鼠中,22 - 氧杂 - 1α,25 - D(3)以剂量依赖性方式直接抑制LLC - GFP细胞的转移活性,而不对宿主中的血钙活性或22 - 氧杂 - 1α,25 - D(3)调节的其他作用产生直接影响。这些结果表明,抑制癌细胞中的转移和血管生成诱导活性似乎是22 - 氧杂 - 1α,25 - D(3)抗癌作用的主要机制。我们的研究结果表明,22 - 氧杂 - 1α,25 - D(3)对预防肺癌转移有益。